>They found that after vaccination, lung infections and damage were indeed significantly reduced, but infections in the nasal cavity did not decrease. Researchers believe that this will have a significant impact on reinfection and vaccines.
Phase 3 of LAG-3 antibody reached the primary endpoint!
Time of Update: 2021-04-20
-3 antibody relatlimab and anti-PD-1 antibody Opdivo (nivolumab) can be used in the treatment of newly treated patients with metastatic or unresectable melanoma. In Phase 2/3 clinical trials, the primary endpoint of progression-free survival
Cell new article: Some new coronavirus mutations can escape neutralizing antibodies
Time of Update: 2021-04-19
In order to accelerate the research progress of the new crown virus, Yiqiao Shenzhou specially launched: new crown recombinant protein, cytokine, ELISA kit, gene and other four categories of products are 40% off, and 30,000+ products are on hot promotion!
Antibody | Looking at the research and development overview of the popular target Claudin 18.2 from the FDA approval of TJ-CD4B in Phase 1 clinical trials
Time of Update: 2021-04-19
2 in multiple cancer tissues and the high positive rate in patients with specific cancers such as gastric cancer and pancreatic cancer that make the targeted therapy and tumor immunotherapy developed around Claudin 18.
Johnson & Johnson BCMA/CD3 dual antibody application for clinical application
Time of Update: 2021-04-19
On April 1, the CDE official website showed that the clinical trial application of Johnson & Johnson's BCMA/CD3 bispecific antibody Teclistamab injection (acceptance number: JXSL2101002/3) was accepted by the CDE.
Fuhong Henlius plans to submit a listing application for phase 2 clinical trial of anti-PD-1 antibody reaching the primary endpoint
Time of Update: 2021-04-19
The primary endpoint reached this time is a single-arm, open, multiple-arm, open-ended, multiple-arm, open-ended, multiple-arm, unresectable or metastatic MSI-H or dMMR solid tumor patient who has failed standard treatments to evaluate the efficacy, safety, and tolerability of HLX10.
Orphan Drug Weekly | Novartis Pancreatic Cancer Antibody Therapy, Bristol-Myers Squibb Protein Degradation Therapy Finalists
Time of Update: 2021-04-19
Drug: Cereblon E3 ligase modulatorResearch and development company: Bristol-Myers Squibb/XinjiTreatment of diseases: Acute myeloid leukemia (AML)Introduction: Cereblon E3 ligase modulator has immunomodulatory and pro-apoptotic activities.
Kangfang Bio-IL-4R monoclonal antibody was approved for clinical indication for moderate to severe atopic dermatitis
Time of Update: 2021-04-18
On April 8, the CDE official website showed that Kangfang Biologics Class 1 new drug AK120 injection was approved for clinical use, and the indication is moderate to severe atopic dermatitis.
BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use
Time of Update: 2021-04-18
On April 9, 2021, the CDE official website showed that BeiGene TIGIT monoclonal antibody BGB-A1217 injection was approved for clinical use, and the indication is advanced solid tumors.
Gilead's Trop-2 antibody conjugate drug gains second indication
Time of Update: 2021-04-18
S. FDA has accelerated the approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand its scope of use for the treatment of locally advanced or metastatic urothelium Cancer patients.
Express | Gilead's Trop-2 antibody-conjugated drug gains second indication for the treatment of bladder cancer
Time of Update: 2021-04-18
S. FDA has accelerated its approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand the scope of use for local treatment Patients with advanced or metastatic urothelial cancer.
JNNP: A prospective study of cancer survival in patients with HuD antibody-related paraneoplastic neurological diseases
Time of Update: 2021-04-17
However, in previous retrospective studies, the survival rate of patients with Hu antibody-related PNDs (Hu-Ab/PNDs) was similar to that of patients with small cell lung cancer (SCLC) without neurological disease.
PD-L1/CTLA-4 bispecific antibody!
Time of Update: 2021-04-17
News on April 14, 2021 /
Study: AstraZeneca vaccine can cause extremely high levels of antibodies to cause blood clots
Time of Update: 2021-04-17
-height: 30px"> Norwegian research shows that: AstraZeneca vaccine can cause extremely high levels of antibodies, leading to serious side effects of blood clots
JNNP: The change rate of acetylcholine receptor antibody levels predicts the prognosis of myasthenia gravis
Time of Update: 2021-04-17
In this study, the purpose of this article is to determine whether the newly developed rate of reduction of AChR-Ab levels (RR-AChRAb) measured before and after immunosuppressive therapy in this study reflects treatment response and predicts the prognosis of MG.
recognition mechanism based on kitatamycin monoclonal antibody in animal tissues
Time of Update: 2021-04-16
In this study, we prepared KIT-specific antigens and developed monoclonal antibodies, and established ic-ELISA methods and sample preparation methods in animal tissues to monitor KIT residues.
CD47 monoclonal antibody is beginning to show its strength!
Time of Update: 2021-04-16
is excellent. Single-drug efficacy has been observed in solid tumors, and the dose climbs up to 30 mg/kg without hematological toxicity, which is excellent.
How long can the antibodies produced by the body last after being vaccinated with the new crown vaccine?
Time of Update: 2021-04-16
> If the test is effective, the laboratory conditions it needs are different from our routine clinical antibody test, because it requires live virus , It is necessary to use a P3 (Biosafety Protection Level 3) laboratory to detect the neutralizing
Sanofi's CD38 antibody combination therapy receives FDA approval to reduce the risk of disease progression by 45%
Time of Update: 2021-04-14
